Chapter 1. Research Background

1.1 Research Objectives

1.2 Definition

1.3 Research Scope

1.3.1 Pipeline Analysis by Phase

1.3.2 Pipeline Analysis by Molecule Type

1.3.3 Pipeline Analysis by Route of Administration

1.4 Key Stakeholders

Chapter 2. Research Methodology

2.1 Secondary Research

2.2 Primary Research

2.2.1 By Industry Participant

2.2.2 By Company Type

Chapter 3. Executive Summary

Chapter 4. Pipeline Outlook

4.1 Overview

4.2 Key Drivers

4.2.1 Increasing Prevalence of Cancer and Rising Healthcare Cost

4.2.2 Technical Advancements

4.3 Key Barrier

4.3.1 Safety Concerns and Risk factors

4.4 mTOR Inhibitor Therapeutics Pipeline Analysis

4.4.1 Pipeline Analysis by Phase

4.4.2 Pipeline Analysis by Molecule Type

4.4.3 Pipeline Analysis by Route of Administration

4.4.4 Pipeline Analysis by Company

Chapter 5. mTOR Inhibitor Therapeutics Pipeline Analysis by Phase (2017) 30

5.1 Phase III

5.1.1 Ipatasertib

5.1.1.1 Clinical trials

5.1.1.2 Clinical results

5.1.1.3 Strategic developments

5.1.2 XXXX

5.1.2.1 Clinical trials

5.2 Phase II

5.2.1 LY3023414

5.2.1.1 Clinical trials

5.2.2 XXXX

5.2.2.1 Pre-Clinical studies

5.2.2.2 Clinical trials

5.2.2.3 Clinical results

5.2.2.4 Others

5.2.3 XXXX

5.2.3.1 Clinical trials

5.2.3.2 Strategic developments

5.2.4 XXXX

5.2.4.1 Clinical trials

5.2.4.2 Clinical results

5.2.4.3 Strategic developments

5.2.5 XXXX

5.2.5.1 Clinical trials

5.2.5.2 Strategic developments

5.2.5.3 Grant

5.2.5.4 Technology

5.2.6 XXXX

5.2.6.1 Clinical trials

5.2.6.2 Designation

5.2.7 XXXX

5.2.7.1 Clinical trials

5.2.7.2 Clinical results

5.2.8 XXXX

5.2.8.1 Pre-Clinical Studies

5.2.8.2 Clinical trials

5.2.8.3 Clinical results

5.2.8.4 Strategic developments

5.2.8.5 Designation

5.2.8.6 Grant

5.3 Phase I

5.3.1 VDC597

5.3.2 XXXX

5.3.2.1 Clinical trials

5.4 Pre-Clinical

5.4.1 VPE001

5.4.1.1 Strategic developments

5.4.2 XXXX

5.4.2.1 Pre-Clinical studies

5.4.2.2 Others

5.4.3 XXXX

5.4.3.1 Technology

5.4.3.2 Strategic developments

5.4.4 XXXX

5.4.4.1 Technology

5.4.5 XXXX

5.4.6 XXXX

5.4.6.1 Technology

5.4.6.2 Designation

5.4.7 XXXX

5.4.7.1 Others

5.4.7.2 Technology

5.4.8 XXXX

5.4.8.1 Pre-Clinical studies

5.4.8.2 Strategic developments

5.4.8.3 Technology

5.5 Discovery

5.5.1 VEA005

5.5.1.1 Strategic developments

5.5.2 XXXX

5.5.2.1 Strategic developments

5.5.3 XXXX

5.5.3.1 Strategic developments

5.5.4 XXXX

5.5.4.1 Strategic developments

5.5.5 XXXX

5.5.5.1 Strategic developments

5.5.5.2 Technology

5.5.6 XXXX

5.5.6.1 Others

5.5.7 XXXX

5.5.7.1 Technology

5.6 Unknown Phase

5.6.1 Non-Steroidal Small Molecule Drug

5.7 Discontinued

Chapter 6. Clinical Trials Analysis

6.1 Clinical Trials by Region for mTOR Inhibitors Therapeutics Pipeline Analysis 2017

6.2 Clinical Trials by Trial Status for mTOR Inhibitors Therapeutics Pipeline Analysis 2017

Chapter 7. Competitive Landscape

7.1 Key Players Benchmarking for mTOR inhibitors Therapeutics Pipeline

7.2 SWOT Analysis of mTOR inhibitor Therapeutics Pipeline

7.2.1 Strengths

7.2.2 Weaknesses

7.2.3 Opportunities

7.2.4 Threats

Chapter 8. Company Profiles

8.1 Eli Lilly & Company

8.1.1 Business Overview

8.1.2 Product & Service Offerings

8.2 AstraZeneca Plc

8.2.1 Business Overview

8.2.2 Product & Service Offerings

8.3 Company 3

8.3.1 Business Overview

8.3.2 Product & Service Offerings

8.4 Company 4

8.4.1 Business Overview

8.4.2 Product & Service Offerings

8.5 Company 5

8.5.1 Business Overview

8.5.2 Product & Service Offerings

8.6 Company 6

8.6.1 Business Overview

8.6.2 Product & Service Offerings

8.7 Company 7

8.7.1 Business Overview

8.7.2 Product & Service Offerings

8.8 Company 8

8.8.1 Business Overview

8.8.2 Product & Service Offerings

8.9 Company 9

8.9.1 Business Overview

8.9.2 Product & Service Offerings

8.1 Company 10

8.10.1 Business Overview

8.10.2 Product & Service Offerings

Chapter 9. Appendix

9.1 Abbreviations

9.2 Related Reports

LIST OF TABLES

TABLE 1 PIPELINE ANALYSIS OF MTOR THERAPEUTICS, BY COMPANY (2017)

TABLE 2 DESCRIPTION OF IPATASERTIB

TABLE 3 CLINICAL TRIALS OF IPATASERTIB

TABLE 4 DESCRIPTION OF XXXX

TABLE 5 CLINICAL TRIALS OF XXXX

TABLE 6 DESCRIPTION OF LY3023414

TABLE 7 CLINICAL TRIALS OF LY3023414

TABLE 8 DESCRIPTION OF XXXX

TABLE 9 CLINICAL TRIALS OF XXXX

TABLE 10 DESCRIPTION OF XXXX

TABLE 11 DESCRIPTION OF XXXX

TABLE 12 CLINICAL TRIALS OF XXXX

TABLE 13 DESCRIPTION OF XXXX

TABLE 14 CLINICAL TRIALS OF XXXX

TABLE 15 DESCRIPTION OF XXXX

TABLE 16 CLINICAL TRIALS OF XXXX

TABLE 17 DESCRIPTION OF XXXX

TABLE 18 CLINICAL TRIALS OF XXXX

TABLE 19 DESCRIPTION OF XXXX

TABLE 20 CLINICAL TRIALS OF XXXX

TABLE 21 DESCRIPTION OF VDC597

TABLE 22 DESCRIPTION OF XXXX

TABLE 23 CLINICAL TRIALS OF XXXX

TABLE 24 DESCRIPTION OF VPE001

TABLE 25 DESCRIPTION OF XXXX

TABLE 26 DESCRIPTION OF XXXX

TABLE 27 DESCRIPTION OF XXXX

TABLE 28 DESCRIPTION OF XXXX

TABLE 29 DESCRIPTION OF XXXX

TABLE 30 DESCRIPTION OF XXXX

TABLE 31 DESCRIPTION OF XXXX

TABLE 32 DESCRIPTION OF VEA005

TABLE 33 DESCRIPTION OF XXXX

TABLE 34 DESCRIPTION OF XXXX

TABLE 35 DESCRIPTION OF XXXX

TABLE 36 DESCRIPTION OF XXXX

TABLE 37 DESCRIPTION OF XXXX

TABLE 38 DESCRIPTION OF XXXX

TABLE 39 DESCRIPTION OF NON-STEROIDAL SMALL MOLECULE DRUG

TABLE 40 DESCRIPTION OF DISCONTINUED DRUGS

TABLE 41 ELI LILLY & COMPANY – AT A GLANCE

TABLE 42 ASTRAZENECA PLC – AT A GLANCE

TABLE 43 COMPANY 3 – AT A GLANCE

TABLE 44 COMPANY 4 – AT A GLANCE

TABLE 45 COMPANY 5 – AT A GLANCE

TABLE 46 COMPANY 6 – AT A GLANCE

TABLE 47 COMPANY 7 – AT A GLANCE

TABLE 48 COMPANY 8 – AT A GLANCE

TABLE 49 COMPANY 9 – AT A GLANCE

TABLE 50 COMPANY 10 – AT A GLANCE

LIST OF FIGURES

FIG 1 RESEARCH METHODOLOGY

FIG 2 SPLIT OF PRIMARY AND SECONDARY RESEARCH

FIG 3 BREAKDOWN OF PRIMARY RESEARCH BY INDUSTRY PARTICIPANT

FIG 4 BREAKDOWN OF PRIMARY RESEARCH BY COMPANY TYPE

FIG 5 CELL SIGNALING PATHWAYS

FIG 6 GENE RELATED TO MTOR

FIG 7 MTOR INHIBITOR THERAPEUTICS UNDER DEVELOPMENT (2017)

FIG 8 MTOR INHIBITOR THERAPEUTICS PIPELINE SPLIT, BY MOLECULE TYPE (2017)

FIG 9 MTOR THERAPEUTIC PIPELINE SPLIT, BY ROUTE OF ADMINISTRATION (2017)

FIG 10 BREAKDOWN OF CLINICAL TRIALS, BY REGION

FIG 11 BREAKDOWN OF CLINICAL TRIALS, BY TRIAL STATUS

FIG 12 KEY PLAYERS BENCHMARKING

FIG 13 SWOT ANALYSIS